Specialty Pharmacy

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

Stock shelves with boutique and unique products to anchor existing customer, attract new ones.

Pharmacists can coordinate educational programs for patients to normalize quality of life and minimize infusion-related pain.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.

Guselkumab (Tremfya) is a fully human selective IL-23 inhibitor therapy FDA-approved for the treatment of adults with active psoriatic arthritis and with moderate to severe plaque psoriasis.

Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products.

When it comes to individualized treatment, “we can do better,” said John Edwards, vice president of Healthcare Solutions Consulting at SoftServe.

The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares.

PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.

Analysis indicates that a 25-mg dose reduces the condition scores significantly more than a 1mg dose over a 3-week period, but the 10-mg dose did not yield the same results.

Intravenous immunoglobulin is used for several autoimmune and inflammatory conditions, although researchers have not fully understood its specific mechanisms.

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

Poster presentations and speaking sessions at NASP showed the importance of clinical pharmacists in ambulatory care and opportunities to expand specialty pharmacy services in ambulatory care.

Leaders must fully understand the benefits of diversity and create an environment in which it thrives to cultivate and inspire the next generation of inclusive leaders.

A session presenter at the ASCP 2022 Annual Meeting addresses research investigating the value of preventative treatments when patients have a limited life expectancy.

Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody.

Promising data suggest triplet regimens may more effectively treat patients with unresected and metastatic intrahepatic cholangiocarcinoma.

Pharmacists are the premier medication experts within health care, who understand more about medication interactions than most physicians and have the unique ability to prevent complications, improve adherence, and save lives.

Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.

ART also results in a faster decay of plasma HIV RNA and increased HIV CD8+T cell immunity compared with the treatment alone, investigators found.

Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.

Pharmacy Times is gearing up for Kidney Week (Nov. 3-6) by learning about the pharmacological role of kidney care from the president of the American Society of Nephrology.

New evidence suggests that using artificial intelligence can help individualize diagnostics and protocols, including when women should get mammograms and what medications can best suit which people.

Epcoritamab is an investigational subcutaneous bispecific antibody being investigated for the treatment of adult patients with relapsed/refractory large B-cell lymphoma.

A compound often found in citrus fruits, nobiletin, could be a less toxic and more effective treatment for cholangiocarcinoma.

Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.

Inflammation-based prognostic scores can be a valuable tool in assessing the overall survival of patients with intrahepatic cholangiocarcinoma.

Otilimab also inhibits the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.

New clinical outcomes from BICSTaR study indicate sustained impact of the therapy for individuals with HIV.